Nobivac NXT HCPFeLV RSS Authorised This medicine is authorised for use in the European Union feline calicivirosis, feline rhinotracheitis, feline panleucopenia and feline leukemia (self-amplifying RNA particle) vaccineMedicineVeterinaryAuthorised
Page contentsPage contents Overview Product details Authorisation details News on Nobivac NXT HCPFeLV Application under evaluation CVMP opinion European Commission decision OverviewUp-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website Product details Name of medicine Nobivac NXT HCPFeLV Active substance feline herpesvirus 1 (FHV), strain G2620A, livefeline calicivirus (FCV), strain F9, livefeline panleucopenia virus (FPL), strain MW-1, livefeline leukemia virus (FeLV) self-amplifying RNA (saRNA)-particle International non-proprietary name (INN) or common name feline calicivirosis, feline rhinotracheitis, feline panleucopenia and feline leukemia (self-amplifying RNA particle) vaccine Pharmacotherapeutic groupImmunologicals for felidaeOther immunologicals Authorisation details EMA product number EMEA/V/C/006682 News on Nobivac NXT HCPFeLV Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-18 June 202619/06/2026 This page was last updated on 26/08/2026 Share this page